Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zentalis Pharmaceuticals (ZNTL) Equity Ratio (2022 - 2025)

Zentalis Pharmaceuticals has reported Equity Ratio over the past 4 years, most recently at 0.75 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.75 for Q4 2025, down 4.51% from a year ago — trailing twelve months through Dec 2025 was 0.75 (down 4.51% YoY), and the annual figure for FY2025 was 0.75, down 4.51%.
  • Equity Ratio for Q4 2025 was 0.75 at Zentalis Pharmaceuticals, down from 0.77 in the prior quarter.
  • Over the last five years, Equity Ratio for ZNTL hit a ceiling of 0.84 in Q2 2023 and a floor of 0.75 in Q4 2025.
  • Median Equity Ratio over the past 4 years was 0.79 (2024), compared with a mean of 0.79.
  • Peak annual rise in Equity Ratio hit 4.42% in 2024, while the deepest fall reached 7.59% in 2024.
  • Zentalis Pharmaceuticals' Equity Ratio stood at 0.8 in 2022, then fell by 1.49% to 0.79 in 2023, then dropped by 1.17% to 0.78 in 2024, then decreased by 4.51% to 0.75 in 2025.
  • The last three reported values for Equity Ratio were 0.75 (Q4 2025), 0.77 (Q3 2025), and 0.78 (Q2 2025) per Business Quant data.